ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Marker Therapeutics Inc

Marker Therapeutics Inc (MRKR)

2.14
-0.18
(-7.76%)
Cerrado 26 Enero 3:00PM
2.11
-0.03
(-1.40%)
Fuera de horario: 6:31PM

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
2.11
Postura de Compra
1.90
Postura de Venta
6.00
Volume Operado de la Acción
155,967
2.05 Rango del Día 2.36
1.83 Rango de 52 semanas 5.99
Capitalización de Mercado [m]
Precio Anterior
2.32
Precio de Apertura
2.36
Última hora de negociación
Volumen financiero
US$ 329,086
Precio Promedio Ponderado
2.11
Volumen promedio (3 m)
60,721
Acciones en circulación
8,923,490
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-2.30
Beneficio por acción (BPA)
-0.92
turnover
3.31M
Beneficio neto
-8.24M

Acerca de Marker Therapeutics Inc

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops prod... Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Business Services, Nec
Sede
Wilmington, Delaware, USA
Fundado
2006
Marker Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MRKR. The last closing price for Marker Therapeutics was US$2.32. Over the last year, Marker Therapeutics shares have traded in a share price range of US$ 1.83 to US$ 5.99.

Marker Therapeutics currently has 8,923,490 shares in issue. The market capitalisation of Marker Therapeutics is US$20.70 million. Marker Therapeutics has a price to earnings ratio (PE ratio) of -2.30.

MRKR Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.58-21.561338292.692.731.83985612.14109306CS
4-1.2-36.2537764353.313.491.83533602.71746689CS
12-1.98-48.41075794624.095.951.83607213.75539251CS
26-2.6899-56.0407508494.79995.951.83454103.65954821CS
52-2.26-51.71624713964.375.991.83326123.90476568CS
156-3.297-60.9765119295.4079.67990.67063636464.04658504CS
260-29.09-93.237179487231.237.70.670659188315.66648806CS

MRKR - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Marker Therapeutics?
El precio actual de las acciones de Marker Therapeutics es US$ 2.11
¿Cuántas acciones de Marker Therapeutics están en circulación?
Marker Therapeutics tiene 8,923,490 acciones en circulación
¿Cuál es la capitalización de mercado de Marker Therapeutics?
La capitalización de mercado de Marker Therapeutics es USD 20.7M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Marker Therapeutics?
Marker Therapeutics ha negociado en un rango de US$ 1.83 a US$ 5.99 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Marker Therapeutics?
El ratio precio/beneficio de Marker Therapeutics es -2.3
¿Cuál es el ratio de efectivo a ventas de Marker Therapeutics?
El ratio de efectivo a ventas de Marker Therapeutics es 5.71
¿Cuál es la moneda de reporte de Marker Therapeutics?
Marker Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Marker Therapeutics?
El último ingresos anual de Marker Therapeutics es USD 3.31M
¿Cuál es el último beneficio anual de Marker Therapeutics?
El último beneficio anual de Marker Therapeutics es USD -8.24M
¿Cuál es la dirección registrada de Marker Therapeutics?
La dirección registrada de Marker Therapeutics es CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Marker Therapeutics?
La dirección del sitio web de Marker Therapeutics es www.markertherapeutics.com
¿En qué sector industrial opera Marker Therapeutics?
Marker Therapeutics opera en el sector BUSINESS SERVICES, NEC

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
EVAXEvaxion Biotech AS
US$ 5.99
(64.56%)
55.41M
ELABPMGC Holdings Inc
US$ 3.0901
(56.07%)
76.48M
PCLAPicoCELA Inc
US$ 4.60
(49.35%)
3.75M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
GODNUGolden Star Acquisition Corporation
US$ 3.11
(-75.82%)
17.51k
GODNGolden Star Acquisition Corporation
US$ 2.93
(-65.67%)
902.76k
NXTTNext Technology Holding Inc
US$ 1.37
(-54.93%)
2.56M
SGLYSingularity Future Technology Ltd
US$ 1.625
(-38.45%)
917.77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90.11
(-38.07%)
8
ACONAclarion Inc
US$ 0.0557
(28.94%)
811.91M
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
RIMEAlgorhythm Holdings Inc
US$ 0.0357
(4.69%)
284.97M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
NVDANVIDIA Corporation
US$ 142.62
(-3.12%)
232.88M

MRKR Discussion

Ver más
Phantom Lord Phantom Lord 1 día hace
I haven't done any research into that ticker or any other stem cell companies so I don't have an opinion.
👍️ 1
bar1080 bar1080 1 día hace
I'm a retired lawyer. I collect atrocious stocks.
🙈 1 🙉 1
CorsairNavigator20 CorsairNavigator20 1 día hace
Why are you here? Kick a stock when it is down. Are you with the Kennedie group as well? I would suggest you read a book, you will have a more productive time.
👍️ 1
bar1080 bar1080 2 días hace
Correction: "I don't own an itty bitty biomeds. Most are rubbish."

s/b I don't own ANY itty bitty biomeds. Most are rubbish.
👍️0
bar1080 bar1080 2 días hace
I don't own an itty bitty biomeds. Most are rubbish.
👍️0
travayl travayl 2 días hace
Maybe you should sell and move on?
👍️ 1
bar1080 bar1080 2 días hace
What a piece of junk this stock is!
👍️0
ShadowHaven59 ShadowHaven59 3 días hace
Thank you 👍 I apologize if this is not appropriate, I was just wondering what your opinion was on stem cell companies. I have a boatload of shares of the company LCTX. I was just wondering what your opinion is about that research. Thank you either way if you respond or don’t.
👍️0
Phantom Lord Phantom Lord 3 días hace
Never trust analyst price targets on these small biotech companies. There are always ulterior motives.
👍️ 2
learningcurve2020 learningcurve2020 3 días hace
Hey Mod, this idiot exist to stalk me and contributes nothing to either board. Please have him removed. Thanks.
👙 1 👚 1
KIPK KIPK 3 días hace
ALL LC2020 Posts are totally IRRELEVANT!!!
👍️ 1 💯 2 🚀 1
learningcurve2020 learningcurve2020 3 días hace
It’s important to keep this guy’s name at the top just for accountability’s sake. Don’t let the link just disappear.

Dr. Huseynov:

https://www.moomoo.com/news/post/44817152/ladenburg-thalmann-maintains-marker-therapeutics-mrkrus-with-buy-rating-raises?level=2&data_ticket=1737645360288002

https://stockanalysis.com/analysts/aydin-huseynov/

https://www.benchmarkcompany.com/the-benchmark-company-expands-its-biotechnology-focus-with-the-addition-of-dr-aydin-huseynov-and-dr-okechukwu-linton/
👗 1 👙 1
learningcurve2020 learningcurve2020 4 días hace
Yep.  Professor Vera and that Director guy who now owns Marker's manufacturing wing, are not giving shareholders anything to smile about.  
👗 1 👙 1
learningcurve2020 learningcurve2020 4 días hace
Most likely answer is he was used to suck in retail then trap them.  
👙 1 🚫 1
bar1080 bar1080 5 días hace
Of course, you'll be tempted to average down... and down and down. Most of us know the drill. Seen it many times, including the BKs and suicides


BTW, I had another good day with my blue chips.
👍️0
microcapbiotech microcapbiotech 5 días hace
Oh My, well it's just set it and forget it for the next 12 months. There will be no reason for a large price upswing without good new data news, and THAT is a Long Way Off.
If it gets below $1.50, I might be tempted to buy more, but not now.
👍️0
bar1080 bar1080 5 días hace
Small biomeds are jokes and so are the "analysts." Please people, smarten up. Some here, lose over and over.
🤬 2
ShadowHaven59 ShadowHaven59 5 días hace
How and why did this analyst give this company a double digit price target after speaking to the company? this is very frustrating.
👍️0
ah86 ah86 5 días hace
Damn! And to think we were at $5 not too long ago dreaming about the teens.
👍️0
ah86 ah86 5 días hace
new 52 week low! who is willing to buy more? come on now, we need yall to bid this up!!!
👍️0
microcapbiotech microcapbiotech 5 días hace
No, I don't think they will cut back on grants. In the big picture, the amounts are miniscule to them and they are needed if they want smaller biotech's to have a shot at producing needed therapies.
👍️ 1
ShadowHaven59 ShadowHaven59 6 días hace
I have read that this new administration, will speed up the process of getting drugs approved. Do you guys also think there is a possibility they will cut back on grants given to companies? Thank you.
👍️0
ShadowHaven59 ShadowHaven59 1 semana hace
I emailed them last month to complain like everyone else and they just emailed me back
👍️ 1
CorsairNavigator20 CorsairNavigator20 1 semana hace
When did you get the letter from Marker. I didn't see one.
👍️0
CorsairNavigator20 CorsairNavigator20 1 semana hace
Amen, I am 72 and I don't expect to see the data before I die as well. To me this type of behavior may imply that they have a subset which will respond well. The bad news is they will not say how big the patient population will be. I consider the AML relapse to be a dead indication, not sure if I go before the phase 3 is complete.
I am here for pancreatic, even in phase 1 data will tell if it's worth pursuing.
👍️ 3
microcapbiotech microcapbiotech 1 semana hace
Thank You. At least MRKR is "on track".
I am "on track" to die of old age before this company successfully completes a phase 3 trial with great data.
👍️ 4
ShadowHaven59 ShadowHaven59 1 semana hace
FWIW, I also received an email today from the company. Pretty much it’s the same that everyone else received. they are on track with their internal. enrollment schedule. they want to have a robust data set for the FDA. sorry to repeat the same information everybody else received. I just had to get this off my chest cause I am also frustrated. thank you.
👍️ 2
GoIrish1776 GoIrish1776 2 semanas hace
I didn't say anything about manly.

Congratulations. Last I checked, they don't determine the games winner on which team has the most hits. They determine it on who has more runs...total. :)
👍️ 2
ah86 ah86 2 semanas hace
To argue with bar1080 or other bears is to miss the point they are trying to make - this company disappoints.
I bought Phio Pharmaceuticals for $1.85 sometime back and sold at $5 yesterday. It topped out at $9.79
Do you care to know why it made that run? It reported data on 2 patients, yes! Two!
They now issued an offering. To be clear, they issued the offering AFTER they let the market had fun.
What was the timing of Marker's offering? Yes, at the same fcking time as the data release.
I hope y'all have an exit strategy.
Focus there instead of wasting your time bickering.
👍️ 1
jobynimble jobynimble 2 semanas hace
Preliminary proxy statement, complete filing: https://www.sec.gov/Archives/edgar/data/1094038/000110465925003033/tm253006-1_pre14a.htm

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
To Be Held On March 21, 2025
👍️ 1
bar1080 bar1080 2 semanas hace
ThanksLC2020 98% of those slobbering gambling addicts would be better off in basic index funds like I and BRK own. But you know that.
👍️0
learningcurve2020 learningcurve2020 2 semanas hace
Why are you guys scolding Bar1080 for telling the truth?
👍️0
microcapbiotech microcapbiotech 2 semanas hace
This is the only kind of forum where it can attempt to build up it's fragile ego that for some sad reason is apparently much needed in it's situation and in it's life.
Being an unwanted lunatic keyboard pansy warrior helps it increase it's obvious lack of self esteem and self worth.
It needs to consult a good psychologist or psychoanalyst to try fill the giant empty void by some productive means,
👍️0
CorsairNavigator20 CorsairNavigator20 2 semanas hace
What are you doing here? You have no interest in the stock, so you are wasting our and your time. Find somewhere else to be productive.
👍️ 2
learningcurve2020 learningcurve2020 2 semanas hace
Guess we can flush Dr. Huseynov's analysis down the toilet. Remember the name is all retail can do.
👍 1 💯 1
learningcurve2020 learningcurve2020 2 semanas hace
THE OFFERING
Common stock outstanding:
10,707,295 shares as of January 10, 2025
Common stock offered by the selling stockholders
10,062,500 shares consisting of (i) 1,783,805 shares of our common stock held by the selling stockholders, (ii) 3,247,445 shares of our common stock issuable upon exercise of outstanding Pre-Funded Warrants to purchase shares of our common stock held by the selling stockholders and (iii) 5,031,250 shares of common stock issuable upon the exercise of outstanding Private Placement Warrants held by the selling stockholders, which we collectively refer to as the Covered Shares
Common stock outstanding after the offering
18,985,990 shares(1)
👍️0
jobynimble jobynimble 2 semanas hace
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

MARKER THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Complete filing: https://www.sec.gov/Archives/edgar/data/1094038/000110465925002600/tm252887-1_s3.htm
👍️ 1
microcapbiotech microcapbiotech 2 semanas hace
bar1080, You just can't stop with your idiotic nonsense statements, can you? You said "Many of the world's great businesses never go public.", YES, but that has NOTHING to do with what I said.
I said "Every stock started out as a startup." Do you see the word "STOCK" you demented fool?
Seriously, what is wrong with you little buzzing gnat that you need to keep getting swatted?
Perhaps you, in all your wisdom should contact every hedge fund billionaire to tell them to just invest in blue chip index funds. After all, hedge fund billionaires need a good laugh too.
P.S. you keep saying things like "Adios", how about doing EVERYBODY a favor and actually mean it and follow through on your words.
As Yoda said: "Try not, do or do not, there is no try".
👍️0
microcapbiotech microcapbiotech 2 semanas hace
How do I add a Clown emoji that I can use for bar1080?
👍️ 1
bar1080 bar1080 2 semanas hace
Not true at all. "Every stock started out as a startup."

Many of the world's great businesses never go public. They often go public when they want to cash out of a bad business or continue a fat salary perpetually. The scams especially sell stock to the dumb money. Adios.
💯 1
microcapbiotech microcapbiotech 2 semanas hace
What Mr. Index Fund Loon doesn't understand is that every stock started out as a startup. Nvidia, Apple, Microsoft, Tesla, etc., were all startups. Every stock in his index funds were startups.
If you invest in 20 biotech startups and 18 go bankrupt, you lost 1,800%, but if 2 make it big, like MANY HAVE, and go up 5,000%, then simple math is 5,000 X 2 = 10,000 - 1,800 = 8,200% profit.
Up 10,000% = 18,200% profit.
It's companies that I bought when they were small like NVDA, QCOM, VRTX, PCYC, SGEN, ALNY, and many others that make my loss in MRKR a nothing burger.
Mr. Loon is just a dullard coot who has nothing better to do than attempt to start arguments on a stock board page he has nothing to do with to try to fill a psychological need to make himself feel big and important. Somethings large and crucial must be missing in his life to have that need.
👍️ 2
bar1080 bar1080 2 semanas hace
"If you're an adult, you take your lumps." So it's manly to take lumps. LOLOL. Not me. I'm a wimpy. multi-millionaire.

I have a profit in almost everything I own. Blue chips and index funds... and no shilled biomed rubbish.
👍️0
GoIrish1776 GoIrish1776 2 semanas hace
Shark tank is full of mom and pop ideas. It's not real venture capital in my opinion, investing in start-ups that have the opportunity to create massive change. That's why they put in small amounts at sub-$1m prices. It's like local bank lending or something. If you invest in a public entity like MRKR at a $20-30m mc, you better believe they can get a licensed drug that sells to some degree because you need to get to many, many multiples of the current mc.

As for start-ups being terrible bets, 9 of 10 are smoking holes in the ground. But that 1 in 10, that's the juice. That is what you have to look for. That is venture capital. If you don't have the taste for it, that's fine. However, Silicon Valley has created and captured trillions (with a T) in wealth. Investing in start-ups as a strategy is terrific. It's arguably the best asset class out there.

Now, MRKR looks like one of the 9 unfortunately. If you're an adult, you take your lumps, see what you believe, and decide what you want to do. That's where we are currently. I haven't given up hope, but I've grown more skeptical. I also haven't sat on the sidelines chirping. I can live with that.

And GO IRISH!
👍️ 2
bar1080 bar1080 2 semanas hace
My personal losses are zero. Startups are terrible bets especially in biomed and that's assuming fraud isn't involved, and we know how much fraud lurks in penny stocks. It's much easier for a small but profitable business to grow into a bigger, more profitable business. That's what Buffett invests in. (such as his GEICO)

I think the TV program Shark tank does a major disservice in that regard. Clever-sounding ideas are a dime a dozen. Let the small company turn an audited few million in sales and profits... and I might be interested in making a sensible investment.
👍️ 2
learningcurve2020 learningcurve2020 2 semanas hace
The amount of public cash burned up in all these go nowhere biotechs is just staggering. Wonder what the total is in the last twenty years or so?
👍️0
bar1080 bar1080 2 semanas hace
Gee, you're starting to catch on.

"Something tells me this is doing about nothing for the next year."
👍️0
microcapbiotech microcapbiotech 3 semanas hace
Something tells me this is doing about nothing for the next year. I don't expect any earth shattering Lymphoma news for about a year, and I don't expect any meaningful Pancreatic news for about a year or two. I don't even know if they have enough money to last until some kind of good news, really can't count on more grant money coming. But just to stay consistent, I will click on the little green bull and keep waiting and hoping.
👍️0
CorsairNavigator20 CorsairNavigator20 3 semanas hace
At least they know what the product is supposed to be and how it works
👍️0
learningcurve2020 learningcurve2020 3 semanas hace
$30 million market cap now. Priced like a lab experiment with a scientist running the show.
👍️ 2
microcapbiotech microcapbiotech 3 semanas hace
Heading towards the $2's again. Oh Joyous Day. Somebody give these people a big raise and bonus package.
👍️ 1